Itraconazole compositions with improved bioavailability
AssigneesAbbott GmbH & Co. KG, Barrier Therapeutics, Inc.
InventorsGunther Berndl, Matthias Degenhardt, Markus Mäegerlein, Gerrit Dispersyn
Life of this patent
Estimating the term…
Abstract
A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35>ΔHtr (1) (wherein ΔHtr represents the endotherm (J/g) accompanying a transition at about 240° C). The solid dispersion product shows an improved bioavailability.
Claims18
A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the formula
- 0.35>ΔHtr
- wherein ΔHtr represents the endotherm (J/g) accompanying a transition at an endothermic peak temperature in the range of from about 240° C. to about 250° C.
A pharmaceutical dosage form comprising a solid dispersion product of itraconazole and hydroxypropyl methylcellulose, the dosage form providing in vivo plasma levels of itraconazole and hydroxy itraconazole characterized by Cmax of 400 ng/mL or higher, after oral administration of a single dose of 200 mg itraconazole.
Dependencies are inferred from the claim text.